Á. Elekes

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Suzanne F. Jones, E. Rock, R. Kurzrock, 2014, Cancer Chemotherapy and Pharmacology.

Clinical experience with an anti-dysphotopic intraocular lens

P. Vámosi, Á. Elekes, Zsófia Rupnik, 2022, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

G. Tricot, D. Reece, D. White, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America

P. Bierman, I. Flinn, T. Shea, 2013 .

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

T. Habermann, J. Berlin, K. Flaherty, 2018, The oncologist.

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

E. Rock, E. Van Cutsem, B. Melichar, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.